Materials And Products Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicinal Products with the Active Ingredient Hydrocortisone (H02ab09) as Part of a So-Called Open House Model.

Fd2020-23-00108

Fd2020-23-00135

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Siponimod

Veikkaus Oy Research Services

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Abs. 8 Sgb V for the Active Ingredient Denosumab

Conclusion of Non-Exclusive Discount Agreements According to § 130A Abs. 8 Sgb V for the Active Substance Ixekizumab

Fd2020-23-00156

Implantation and Implementation of a Dynamic System of Acquisition of Current Use Supplies Products Available in the Market and Whose General Characteristics are Adapted to the Needs Of...